BCAL Diagnostics Limited (AU:BDX) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
BCAL Diagnostics Limited is gearing up for the commercial launch of their breast cancer detection tool, BREASTEST®, with a new commercial license agreement with Sydney Breast Clinic. The company has also started operations in the US, establishing a subsidiary and securing research facilities, while continuing to enhance its intellectual property portfolio with patents and trademarks. With a cash reserve of $7.1 million and additional funds from R&D tax offsets, BCAL is poised for significant growth and market entry.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.